(Q34327123)

English

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

phase I clinical trial

0 references

15

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

24

object named as

Mark E Davis

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

11

object named as

Edward Garmey

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

author name string

Glen J Weiss

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Joseph Chao

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Jeffrey D Neidhart

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Ramesh K Ramanathan

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Dawn Bassett

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

James A Neidhart

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Chung Hang J Choi

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Warren Chow

8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Vincent Chung

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Stephen J Forman

10

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Jungyeon Hwang

12

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

D Lynn Kalinoski

13

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Marianna Koczywas

14

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Roger J Melton

16

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Robert Morgan

17

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Jamie Oliver

18

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Joanna J Peterkin

19

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

John L Ryan

20

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Thomas Schluep

21

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Timothy W Synold

22

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Przemyslaw Twardowski

23

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Yun Yen

25

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

9 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

986-1000

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

https://scigraph.springernature.com/pub.10.1007/s10637-012-9921-8

0 references

American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Topoisomerase I inhibitors: camptothecins and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Camptothecins and Topoisomerase I; A Foot in the Door. Targeting the Genome Beyond Topoisomerase I with Camptothecins and Novel Anticancer Drugs; Importance of DNA Replication, Repair and Cell Cycle Checkpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

6 July 2018

Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9921-8

21 January 2018

Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774600

27 October 2018

Accelerated titration designs for phase I clinical trials in oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/23397498

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-012-9921-8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34327123&oldid=2116831173"